Drug Trial Radar · NCT02914600
Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease
Last checked: Nov 19, 2026Latest source record: Jul 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,188
Actual
Start
Mar 17, 2017
Primary completion
Aug 1, 2023
Study completion Aug 1, 2023
Sponsor
- Lead sponsor
- Lakefront Biotherapeutics NVIndustry
- Sponsor type
- Industry
- Collaborators
- Gilead Sciences
- First posted
- Sep 26, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in Crohn's disease (CD).
Conditions
- Crohn's Disease
Interventions
FilgotinibDrug
Tablet administered orally once a day
PlaceboDrug
Tablet administered orally once a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: From the First Dose to Week 312
Locations
486 sites in 40 countries. Site status is shown where the registry gives one.
Digestive Health Specialists Of The Southeast
Dothan, Alabama
Arizona Digestive Health - Sun City
Sun City, Arizona
Southern California Research Center, Inc.
Coronado, California
Cedars Sinai Medical Center
Los Angeles, California
Inland Empire Clinical Trials, LLC
Rialto, California
UC San Diego Health Systems
San Diego, California
Kaiser Permanente
San Francisco, California
Clearview Medical Research, LLC
Santa Clarita, California
University of Colorado Denver and Hospital
Aurora, Colorado
South Denver Gastroenterology, PC
Lone Tree, Colorado
Connecticut GI, PC - Research Division
Farmington, Connecticut
Medstar Georgetown University Hospital
Washington D.C., District of Columbia
Advanced Research, LLC
Coral Springs, Florida
UF Clinical Research Center
Gainesville, Florida
Florida Research Institute
Lakewood Rch, Florida
Florida Center for Gastroenterology
Largo, Florida
University of Miami Crohn's and Colitis Center
Miami, Florida
Advanced Pharma CR, LLC
Miami, Florida
Cordova Research Institute
Miami, Florida
Vista Health Research, LLC
Miami, Florida
Gastroenterology Group of Naples
Naples, Florida
Center for Interventional Endoscopy - Florida Hospital
Orlando, Florida
Gulf Region Clinical Research Institute
Pensacola, Florida
Advanced Medical Research Center
Port Orange, Florida
Tampa General Hospital
Tampa, Florida
Florida Medical Clinic, P.A
Zephyrhills, Florida
Gastroenterology Associates Of Central Georgia, LLC
Macon, Georgia
Gastrointestinal Specialists of Georgia
Marietta, Georgia
Atlanta Gastroenterology Specialist, PC
Suwanee, Georgia
Illinois Gastroenterology Group - Arlington Heights
Arlington Heights, Illinois
Northwestern University Feinberg School of Medicine
Chicago, Illinois
The University of Chicago Medical Center (Clinic)
Chicago, Illinois
Illinois Gastroenterology Group - Gurnee
Gurnee, Illinois
Indiana University
Indianapolis, Indiana
University of Iowa Hospitals and Clinics
Iowa City, Iowa
University of Kansas Medical Center
Kansas City, Kansas
University of Louisville, Clinical Trials Unit
Louisville, Kentucky
Delta Research Partners, LLC
Monroe, Louisiana
Louisiana Research Center, LLC
Shreveport, Louisiana
Investigative Clinical Research
Annapolis, Maryland
Showing 40 of 486 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.